Dudley & Shanley’s Biogen BIIB Stock Holding History

Dudley & Shanley’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,000	Closed	-$580K	–	37
2018 Q2	$580K	Hold	2,000	–	–	0.11%	35
2018 Q1	$548K	Buy	+2,000	New	+$621K	0.1%	37

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Dudley & Shanley's BIIB Position: Q3 2018 in Review

Dudley & Shanley sold out of Biogen (BIIB) in Q3 2018, closing a stake of 2,000 shares — an estimated $580K sold.

Dudley & Shanley first reported a position in BIIB in Q1 2018 and held it in 2 quarters. The position peaked at $580K in Q2 2018. 1,145 funds tracked by Wall St. Rank hold BIIB as of Q3 2018.

Dudley & Shanley reported no remaining Biogen position as of Q3 2018 after selling out during the quarter.
Dudley & Shanley sold 2,000 Biogen shares in Q3 2018, an estimated $580K.
Dudley & Shanley first reported a position in Biogen in Q1 2018 and held it in 2 quarters.
Dudley & Shanley's Biogen position peaked at $580K in Q2 2018.
1,145 funds tracked by Wall St. Rank held Biogen as of Q3 2018.

Based on Dudley & Shanley's 13F filing for Q3 2018, filed 29 Oct 2018.